ClinicalTrials.gg
Status unknownNCT00354276Updated Jan 10, 2014

VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia

A Phase 2 interventional study of cytarabine and laromustine in Leukemia, sponsored by Vion Pharmaceuticals. Status unknown at 3 sites in 3 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2014-01-10.

Primary conditionLeukemia, Myeloid, AcuteRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myeloid, Acute
Why
  1. The study's title name Leukemia, Myeloid, Acute, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Vion Pharmaceuticals · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2009), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
85
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.

Planned enrollment
70th of 239
85 · median 48
Started
2006
with 7 others
Phase 2
112 of 247
21 open now
Registered
52nd of 247
by date

Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 70th largest by planned enrollment of the 239 interventional ones that give a count, is one of 8 that started in 2006, is one of 112 in phase 2, and was the 52nd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

34 more — sign in →

By country, each count listing its studies:

All 39 open studies →

About cytarabine

Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies testing cytarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving VNP40101M followed by cytarabine may kill more cancer cells.

PURPOSE: This phase II trial is studying how well VNP40101M followed by cytarabine works in treating older patients with acute myeloid leukemia.

Read the detailed description

OBJECTIVES:

Primary

  • Determine the complete response rate in older patients with poor-risk, de novo acute myeloid leukemia treated with VNP40101M as induction therapy followed by cytarabine as consolidation therapy.

Secondary

  • Determine the probability of overall survival, leukemia-free survival, and progression-free survival of patients treated with this regimen.
  • Determine the safety of this regimen in these patients.

OUTLINE: This is an open-label, multicenter study.

  • Induction therapy: Patients receive VNP40101M IV over 60 minutes on day 1 (course 1). Patients without evidence of disease progression who have responding but residual disease receive a second course of VNP40101M once between days 35-60. Patients achieving complete response or partial response after induction therapy proceed to consolidation therapy.
  • Consolidation therapy: Beginning between days 45-90, patients receive cytarabine IV continuously over 5 days (course 1). Patients may receive a second course of cytarabine at the discretion of the investigator.

After completion of study treatment, patients are followed periodically for up to 36 months.

PROJECTED ACCRUAL: A total of 85 patients will be accrued for this study.

03

Conditions studied

  • Leukemia

Keywords

  • adult acute myeloid leukemia with 11q23 (MLL) abnormalities
  • adult acute myeloid leukemia with t(16;16)(p13;q22)
  • untreated adult acute myeloid leukemia
  • adult acute myelomonocytic leukemia (M4)
  • adult acute monocytic leukemia (M5b)
  • adult erythroleukemia (M6a)
  • adult pure erythroid leukemia (M6b)
  • adult acute monoblastic leukemia (M5a)
  • adult acute megakaryoblastic leukemia (M7)
  • adult acute basophilic leukemia
  • adult acute myeloblastic leukemia without maturation (M1)
  • adult acute myeloblastic leukemia with maturation (M2)
  • adult acute eosinophilic leukemia
  • adult acute minimally differentiated myeloid leukemia (M0)
04

In context

Leukemia, Myeloid, Acute Reclassified

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

This study's planned enrollment of 85 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Vion Pharmaceuticals is the lead sponsor of 20 studies on the registry; none are open to participants now.

Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed de novo acute myeloid leukemia (AML)

    • No acute promyelocytic leukemia [t(15;17)]
    • No favorable cytogenetics, including t(15;17), t(8;21), or inv 16
    • No secondary AML, defined as having a history of an antecedent hematologic disorder (myelodysplastic syndromes [MDS] or myeloproliferative disease), or history of prior chemotherapy or radiation for a disease other than AML
  • Must have ≥ 1 of the following poor-risk features:

    • Any of the following unfavorable cytogenetics:

      • Del (5q)/-5q
      • -7/del(7q)
      • Abnormal 3q, 9q, 11q, 20q, 21q, or 17p
      • t(6;9)
      • t(9;22)
      • Trisomy 8
      • Complex karyotypes (≥ 3 unrelated abnormalities)
    • At least 70 years of age
    • performance status (PS) of 2
    • Cardiac dysfunction* that would limit the use of anthracycline therapy, as defined by any of the following:

      • ≤ 50%
      • History of significant coronary artery disease, defined as ≥ 1 vessel stenosis requiring medical treatment, stent placement, or surgical bypass graft
      • History of congestive heart failure or myocardial infarction
      • Significant arrhythmia, including any of the following:

        • Atrial flutter (excluding atrial fibrillation)
        • Sick sinus syndrome
        • Ventricular arrhythmia
      • Heart valve disease

        • Mitral valve prolapse allowed
      • Other heart disease, at the discretion of the principal investigator
    • Pulmonary dysfunction not related to AML, defined by 1 of the following:

      • DLCO and/or FEV_1 \< 80% and ≥ 50% normal range
      • Dyspnea on slight activity or at rest
      • Requires oxygen
    • Hepatic dysfunction related to chronic hepatitis or liver cirrhosis
    • Other organ dysfunction or comorbidity that precludes standard cytotoxic induction treatment (e.g., "3+7"), at the discretion of the principal investigator NOTE: *Patients with a history of heart disease as defined above must be on appropriate medication and have their disease under control
  • No known CNS disease

PATIENT CHARACTERISTICS:

  • ECOG PS 0-2
  • and ALT ≤ 5 times
  • ≤ 2.0 mg/dL
  • Creatinine ≤ 2.0 mg/dL
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective during and for 6 months after completion of study treatment
  • No active, uncontrolled infection

    • Patients with an infection who are under active treatment with antibiotics and whose infections are controlled are eligible
    • Chronic hepatitis allowed
  • No clinical evidence of ongoing second unrelated to AML or MDS
  • No evidence of left bundle branch block on screening
  • No obligate use of cardiac pacemaker or atrial fibrillation

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 24 hours since prior metronidazole
  • No prior low-dose, single-agent, cytotoxic chemotherapy (e.g., cytarabine, decitabine, or azacitidine)
  • No concurrent disulfiram
  • No other concurrent standard or therapy for AML except for the following:

    • Concurrent hydroxyurea to control rising white blood cell counts

      • Dosage must be 4-6 grams daily for up to 4 days
    • Concurrent leukapheresis to control blast cell counts

      • Must be completed within the first 5 days of study therapy
      • No more than 2 procedures per day or 4 procedures total
    • Investigational supportive care agents (e.g., antimicrobials or antifungal agents), at the discretion of the protocol sponsor
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
None (open label)
Enrollment
85 participants (estimated)

Interventions

07

What researchers measure

Primary outcomes

  1. Complete response rate

Secondary outcomes

  1. Leukemia-free survival

08

Study locations

3 sites
  • Jonsson Comprehensive Cancer Center at UCLA
    Los Angeles, California 90095-1781, United States
  • Hopital Haut Leveque
    Pessac, 33604, France
  • University Hospital of Wales
    Cardiff, Wales CF14 4XW, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006 and a primary completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2006
First posted
Jul 20, 2006
Start
May 2006
Primary completionEst.
Dec 2008
Last update
Jan 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00354276
Lead sponsor
Vion Pharmaceuticals
First posted
Jul 20, 2006
Start date
May 2006
Primary completion
Dec 2008 (estimated)
Last update
Jan 10, 2014

Study contacts

Bonny L. Johnson, RN, MSN
Vion Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytarabine

Start the discussion